Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. - Wikidata - awgldk - TriplyDB

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

http://www.wikidata.org/entity/Q34582444

about

MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention PPARs and the cardiovascular system AMPK and PPARdelta agonists are exercise mimetics An ethanol extract of Artemisia iwayomogi activates PPARδ leading to activation of fatty acid oxidation in skeletal muscle PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.The application of transcriptomic data in the authentication of beef derived from contrasting production systems.Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta.PPARbeta activation induces rapid changes of both AMPK subunit expression and AMPK activation in mouse skeletal muscle.Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.Peroxisome proliferator-activated receptors for hypertension.Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists.Role of prostacyclin in pulmonary hypertension.Generation and characterization of a humanized PPARδ mouse model Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function.Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Future therapeutic directions in reverse cholesterol transport.Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Vascular effects of prostacyclin: does activation of PPARδ play a role?Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.PPARδ activation protects endothelial function in diabetic mice.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.PPAR Agonists and Cardiovascular Disease in Diabetes.Should We Use PPAR Agonists to Reduce Cardiovascular Risk?Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.Trust your gut: galvanizing nutritional interest in intestinal cholesterol metabolism for protection against cardiovascular diseases PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis Drug discovery in the metabolic syndrome: context and some recent developments.Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.Metabolic syndrome management.

P2860

Q21342745-BF0E4821-4A4D-4FAB-AC9B-9AA85ADD9997 Q24601222-B79F701E-9B67-401B-B412-5C025D32BA40 Q24642728-C2FE46F3-A9F0-41C8-A957-AC03E9036496 Q24652674-6983ADC0-A9B6-4542-B70F-93888CCB3634 Q28730913-E82982A2-D430-451F-92A2-AAE0952BEFCC Q30241952-AE7804C8-7D2F-401A-88C3-415F86D6B1AB Q31132226-B152144B-45DC-4DAF-AED5-D4E9494FC058 Q33503634-ED3A3332-611E-4DF9-BA74-11A942B93FB3 Q33636870-4D81CFCA-3520-4135-8A36-7F8DB733120C Q33660599-6DD8DD9B-A750-48B6-BAAC-ADAC48DE10ED Q33705041-9EAEB8B6-20F5-4FCD-AD04-F0BF99475AEC Q34035340-3C80C321-D2B9-4919-98BE-0CE46C5BE898 Q34036950-15A48955-5620-41A4-B7A3-48745399257D Q34041838-2D3F8194-7A64-4F34-8A75-88C06CEEC90C Q34179017-0646C6F4-C64B-4A10-9324-D0227FD907F9 Q34206025-05C682C8-2345-4E2B-8C1B-591237BD6070 Q34398065-7978ACC8-5850-415F-840A-8DB79758FF45 Q34403000-DE163926-0B18-422D-AA25-015D13F12F7C Q35165100-D58D3F96-7C75-4DA3-8F8B-17DFFE6CB7DD Q35210055-82AA08ED-55C6-459B-BBEE-458ECA14A928 Q35569436-59C44338-3D86-4188-9860-125217737C9D Q35613331-7CDBE6A7-A4B8-48D5-9ADB-666EBD9227B7 Q35636191-88C2FD77-D053-4A5A-A723-4039478E34F1 Q35860010-A3D4BF1F-139B-426E-A7B2-BBDFE4F71FB6 Q36067442-9ADCC645-2E66-4ABA-B97F-AA14808821F6 Q36253614-D2D2084D-D29D-4951-8898-65D6B1F82ABC Q36287741-5231C540-594C-4ADA-B957-AF9DE46CCBFF Q36352434-A6F1C2BD-9BFD-4432-BF04-4B4C280B3EC5 Q36363679-7BBD71C4-93C2-4E8B-BF5D-6C59366AF3E3 Q36404963-615566C2-9BD2-4F30-955C-77C8B46461C9 Q36410664-9CE3FD8E-F8CA-4550-8D77-7075AEB180BA Q36419283-F48652DD-8E38-4FC4-A8F7-5B779901C9F3 Q36444975-98B62D30-0E52-445C-80B6-07C69A62F8FF Q36446970-4CF82C31-2DAE-45DC-9C7F-014E76B40C39 Q36515591-AE352226-914C-4A6E-8AE1-F51CDD02747C Q36607669-02145156-EEE7-47E0-9970-7CACED6A9670 Q36670249-5E77AA80-9C50-4F76-A4DF-CDA8BF0551B3 Q36822448-3C991EBE-AFAB-457D-B2A8-74BBA46C21FA Q36845108-2DB0E769-C4F6-46B1-84ED-D297C3C39740 Q36916909-A5C8C27F-523E-42BA-AD10-2E6FA3844B93

P2860

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

http://www.wikidata.org/entity/Q34582444

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@ast

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@en

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@nl

type

label

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@ast

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@en

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@nl

prefLabel

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@ast

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@en

Triglyceride:high-density lipo ...... ivated receptor delta agonist.

@nl

P1433

Q34582444-ADDAED4A-2960-410C-91EE-F439674EF678

P1476

Q34582444-10AAD0AA-94E8-4C68-8AF0-008BAA552767

P2093

Q34582444-0A1E46EE-9D2E-4276-B8AB-F2A160AFB882

Q34582444-49BAD9F5-DE17-48B3-9178-3B30CFCA588C

Q34582444-5F3F0501-E043-451D-82F1-BC872650C49C

Q34582444-7F49D351-F8CD-4B2C-AD01-3D8C4215DFCD

Q34582444-8F72AED9-F5CB-46F3-B42C-E0CD20B3B222

Q34582444-94B00F15-8E9F-4EE6-9F2C-66DF899958F9

Q34582444-C9311CCE-9D5B-47B0-9178-6333701A232C

Q34582444-DB05A01D-E37A-4990-9598-79C6B8F5DB15

Q34582444-DFAC7A19-8447-4F97-9EB2-1F832D9BC287

Q34582444-FB0CFDBF-775A-47CD-A6E2-E83430C9AB1E

P304

Q34582444-34D86C91-FD3D-43A5-BD2C-E4405CB505F9

P31

Q34582444-022174C9-68E5-4089-9E30-6048E3BF2C8C

P356

Q34582444-9E64216E-229B-4E7D-B53E-E3EF2D499DDC

P407

Q34582444-E0D420E8-B4DD-4705-9F8E-2FA9E633EE88

P433

Q34582444-25667200-967B-4FA2-BEDA-4D4D6E184CB1

P478

Q34582444-E190DEAB-2072-45DA-8D18-99DC02DC771A

P50

Q34582444-6B36D5D1-FA27-47E1-9832-7B962F4C0A45

P577

Q34582444-43C3A084-5050-4743-8C94-2908A75E9827

P698

Q34582444-437132D8-4AB9-4885-BBF8-48F096FDCEB2

P921

Q34582444-0A2FD024-369A-4FD1-8A2E-4D3693C1E25B

Q34582444-3284D726-3941-457D-9035-4F058816C423

Q34582444-83830EDE-E4F9-4A2F-AA7D-A059A17E443F

P356

01.ATV.0000252790.70572.0C

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Triglyceride:high-density lipo ...... tivated receptor delta agonist

@en

P2093

Christine Massien

http://www.w3.org/2001/XMLSchema#string

David C Lobe

http://www.w3.org/2001/XMLSchema#string

David G Hassall

http://www.w3.org/2001/XMLSchema#string

Dennis L Sprecher

http://www.w3.org/2001/XMLSchema#string

Greg Pearce

http://www.w3.org/2001/XMLSchema#string

Itay Perlstein

http://www.w3.org/2001/XMLSchema#string

Nicolas Ancellin

http://www.w3.org/2001/XMLSchema#string

Scott D Patterson

http://www.w3.org/2001/XMLSchema#string

Timothy M Willson

http://www.w3.org/2001/XMLSchema#string

Tony G Johnson

http://www.w3.org/2001/XMLSchema#string

P304

359-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.ATV.0000252790.70572.0C

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17110604

http://www.w3.org/2001/XMLSchema#string

P921

HDL cholesterol